MAZE Stock Forecast & Price Target

Maze Therapeutics is supported by a genetically validated precision-medicine platform and a focused pipeline in CKD, with MZE829 and MZE782 offering multiple shots on goal in high-unmet-need CVRM diseases. The outlook is strengthened by recent VRTX APOL1 data that de-risks MZE829 while still leaving room for differentiation, especially if Maze shows broad proteinuria reductions across AMKD cohorts and clean safety without liver enzyme elevations; earlier preliminary MZE829 data showed about a -49% uACR reduction in AMKD patients without diabetes. Financially, the company’s current cash is described as providing ample runway beyond near-term proof-of-concept readouts, while management also raised R&D spending guidance to match a higher 3Q26 run rate.

Maze Therapeutics is exposed to substantial regulatory risk because accelerated approval pathways may still require additional data, longer studies, or narrower product labels that could weaken commercial traction. Its outlook is also pressured by execution and competition risk, as failure to meet market expectations or compete effectively against branded rivals such as VRTX and Otsuka, as well as generic players and future entrants, could limit uptake. Financially, the company is expected to need additional external funding, and any inability to access capital markets could delay or terminate development efforts across its platform.